Orion Biotech Opportunities Corp.
| IPO Proceeds, $M | $200.00M |
|---|---|
| IPO Date | May 13, 2021 |
| CEO | James Huang |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology and life sciences |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | May 17, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Orion Biotech Opportunities Corp.:
- Structure and cap table
- 7 directors & officers
- 6 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| James Huang | 55 | Chief Executive Officer and Director |
| Chrystyna Bedrij Stecyk | 58 | Vice President |
| Mark Kayal | 36 | Chief Financial Officer and Secretary |
| Robert Simonds | 47 | General Counsel, Assistant Secretary, Vice President and Director |
| Samuel Broder | 76 | Director |
| James Collins | 55 | Director |
| Louisa Rodriguez | 61 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Underwriters | |||
|---|---|---|---|
| Cantor Fitzgerald | BR | 20,000,000 | units |
| 20,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Feb 25, 2021 | Initial S-1 |
| Apr 12, 2021 |
Amended S-1
Sign In to view filing content. |
| May 12, 2021 |
PR announcing pricing of $200mm IPO
Sign In to view filing content. |
| May 14, 2021 | 424B4 IPO Prospectus |
| Jul 1, 2021 |
PR announcing separate trading of shares and warrants
Sign In to view filing content. |
| Apr 24, 2023 |
8-K announcing liquidation and redemption of public shares
Sign In to view filing content. |